{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:49:56Z","timestamp":1794620996675,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cient\u00edficas","doi-asserted-by":"publisher","award":["PIE202250E035; PIE202350E113"],"award-info":[{"award-number":["PIE202250E035; PIE202350E113"]}],"id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cient\u00edficas","doi-asserted-by":"publisher","award":["PIE202250E035; PIE202350E113"],"award-info":[{"award-number":["PIE202250E035; PIE202350E113"]}],"id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cient\u00edficas","doi-asserted-by":"publisher","award":["PIE202250E035; PIE202350E113"],"award-info":[{"award-number":["PIE202250E035; PIE202350E113"]}],"id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cient\u00edficas","doi-asserted-by":"publisher","award":["PIE202250E035; PIE202350E113"],"award-info":[{"award-number":["PIE202250E035; PIE202350E113"]}],"id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cient\u00edficas","doi-asserted-by":"publisher","award":["PIE202250E035; PIE202350E113"],"award-info":[{"award-number":["PIE202250E035; PIE202350E113"]}],"id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n \u201cContigo contra el c\u00e1ncer de la mujer\u201d."},{"DOI":"10.13039\/501100018779","name":"Fundaci\u00f3n FERO","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antibody\u2013Drug Conjugates (ADCs) are a promising cancer treatment that deliver toxic drugs directly to cancer cells, reducing harm to healthy tissue. A key feature of newer ADCs is the \u201cbystander effect,\u201d in which nearby cancer cells are also affected by passive diffusion. However, the mechanisms underlying this effect remain unclear. Using computer simulations, this study investigates how the drug\u2019s ionization state and the linker connecting it to the antibody influence its ability to cross cell membranes. The results show that the ionization state of the drug impacts its membrane permeability, as charged molecules encounter resistance when moving through the membrane\u2019s hydrophobic core. Moreover, the study reveals that the linker increases the drug\u2019s overall size and hydrophobicity, thereby hindering its diffusion to adjacent cells. This finding suggests that linker design can significantly influence the efficacy of antibody\u2013drug conjugates (ADCs) by limiting their ability to reach neighboring cancer cells. These insights enhance our understanding of ADC mechanisms and provide a valuable foundation for the optimization of next-generation ADC therapies targeting breast cancer.<\/jats:p>","DOI":"10.1038\/s41598-025-13810-w","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T08:19:23Z","timestamp":1754468363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["In\u00a0silico decrypting of the bystander effect in antibody\u2013drug conjugates for breast cancer therapy"],"prefix":"10.1038","volume":"15","author":[{"given":"V\u00edctor L.","family":"Cruz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Duro-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Franco-Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Garc\u00eda-Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Gion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Garrig\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantxa","family":"Aguinagalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"13810_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu, Z., Li, S., Han, S., Shi, C. & Zhang, Y. Antibody drug conjugate: The \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct. Target Ther. 7, 93 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"13810_CR2","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher, A. H. & Brown, M. P. Antibody drug conjugates and bystander killing: Is antigen-dependent internalisation required?. Br. J. Cancer 117, 1736\u20131742 (2017).","journal-title":"Br. J. Cancer"},{"key":"13810_CR3","doi-asserted-by":"crossref","unstructured":"Lambert, J. M. & Chari, R. V. J. Ado-trastuzumab Emtansine (T-DM1): An antibody\u2014Drug conjugate (ADC) for HER2-Positive Breast Cancer. (2014).","DOI":"10.1021\/jm500766w"},{"key":"13810_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ddtec.2020.07.002","volume":"37","author":"E Tarcsa","year":"2020","unstructured":"Tarcsa, E., Guffroy, M. R., Falahatpisheh, H., Phipps, C. & Kalvass, J. C. Antibody-drug conjugates as targeted therapies: Are we there yet? A critical review of the current clinical landscape. Drug Discov. Today Technol. 37, 13\u201322 (2020).","journal-title":"Drug Discov. Today Technol."},{"key":"13810_CR5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.drudis.2017.05.011","volume":"22","author":"S Sau","year":"2017","unstructured":"Sau, S., Alsaab, H. O., Kashaw, S. K., Tatiparti, K. & Iyer, A. K. Advances in antibody\u2013drug conjugates: A new era of targeted cancer therapy. Drug Discov. Today 22, 1547\u20131556 (2017).","journal-title":"Drug Discov. Today"},{"key":"13810_CR6","doi-asserted-by":"publisher","first-page":"2100032","DOI":"10.1002\/adfm.202100032","volume":"31","author":"MA Firer","year":"2021","unstructured":"Firer, M. A. & Luboshits, G. Antibody-drug-conjugate therapy for hematological cancers: Matching cell biology with clinical benefit. Adv. Funct. Mater. 31, 2100032 (2021).","journal-title":"Adv. Funct. Mater."},{"key":"13810_CR7","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","volume":"24","author":"F Giugliano","year":"2022","unstructured":"Giugliano, F., Corti, C., Tarantino, P., Michelini, F. & Curigliano, G. Bystander effect of antibody\u2013drug conjugates: Fact or fiction?. Curr. Oncol. Rep. 24, 809\u2013817 (2022).","journal-title":"Curr. Oncol. Rep."},{"key":"13810_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41698-022-00338-9","volume":"7","author":"N Coleman","year":"2023","unstructured":"Coleman, N., Yap, T. A., Heymach, J. V., Meric-Bernstam, F. & Le, X. Antibody-drug conjugates in lung cancer: Dawn of a new era?. NPJ Precis. Oncol. 7, 5 (2023).","journal-title":"NPJ Precis. Oncol."},{"key":"13810_CR9","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.3390\/molecules25122861","volume":"25","author":"D Dahlgren","year":"2020","unstructured":"Dahlgren, D. & Lennern\u00e4s, H. Antibody-drug conjugates and targeted treatment strategies for hepatocellular carcinoma: A drug-delivery perspective. Molecules 25, 2861 (2020).","journal-title":"Molecules"},{"key":"13810_CR10","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/1535-7163.MCT-21-0580","volume":"21","author":"E Khera","year":"2022","unstructured":"Khera, E. et al. Cellular-resolution imaging of bystander payload tissue penetration from antibody-drug conjugates. Mol. Cancer Ther. 21, 310\u2013321 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"13810_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.neo.2020.12.001","volume":"23","author":"E Khera","year":"2021","unstructured":"Khera, E. et al. Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping. Neoplasia (United States) 23, 210\u2013221 (2021).","journal-title":"Neoplasia (United States)"},{"key":"13810_CR12","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2967\/jnumed.118.207753","volume":"59","author":"O Ilovich","year":"2018","unstructured":"Ilovich, O. et al. Dual-isotope cryoimaging quantitative autoradiography: Investigating antibody-drug conjugate distribution and payload delivery through imaging. J. Nucl. Med. 59, 1461 (2018).","journal-title":"J. Nucl. Med."},{"key":"13810_CR13","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1093\/bib\/bbz095","volume":"21","author":"RA Norman","year":"2020","unstructured":"Norman, R. A. et al. Computational approaches to therapeutic antibody design: Established methods and emerging trends. Brief Bioinform. 21, 1549\u20131567 (2020).","journal-title":"Brief Bioinform."},{"key":"13810_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1021\/acs.jcim.0c01312","volume":"61","author":"I Kabelka","year":"2021","unstructured":"Kabelka, I., Bro\u017eek, R. & V\u00e1cha, R. Selecting collective variables and free-energy methods for peptide translocation across membranes. J. Chem. Inf. Model 61, 819\u2013830 (2021).","journal-title":"J. Chem. Inf. Model"},{"key":"13810_CR15","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1021\/acs.jcim.1c00380","volume":"61","author":"M Sugita","year":"2021","unstructured":"Sugita, M. et al. Large-scale membrane permeability prediction of cyclic peptides crossing a lipid bilayer based on enhanced sampling molecular dynamics simulations. J. Chem. Inf. Model 61, 3681\u20133695 (2021).","journal-title":"J. Chem. Inf. Model"},{"key":"13810_CR16","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1021\/acs.jcim.1c01540","volume":"62","author":"S Zhang","year":"2022","unstructured":"Zhang, S. et al. Mechanistic insights into passive membrane permeability of drug-like molecules from a weighted ensemble of trajectories. J. Chem. Inf. Model 62, 1891\u20131904 (2022).","journal-title":"J. Chem. Inf. Model"},{"key":"13810_CR17","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1021\/acs.jpcb.9b11728","volume":"124","author":"JAH Schw\u00f6bel","year":"2020","unstructured":"Schw\u00f6bel, J. A. H. et al. COSMO perm: Mechanistic prediction of passive membrane permeability for neutral compounds and ions and its pH dependence. J. Phys. Chem. B 124, 3343\u20133354 (2020).","journal-title":"J. Phys. Chem. B"},{"key":"13810_CR18","doi-asserted-by":"publisher","first-page":"244114","DOI":"10.1063\/5.0053931","volume":"154","author":"A Dutta","year":"2021","unstructured":"Dutta, A., Vreeken, J., Ghiringhelli, L. M. & Bereau, T. Data-driven equation for drug-membrane permeability across drugs and membranes. J. Chem. Phys. 154, 244114 (2021).","journal-title":"J. Chem. Phys."},{"key":"13810_CR19","doi-asserted-by":"publisher","first-page":"102500","DOI":"10.1016\/j.ctrv.2022.102500","volume":"113","author":"C von Arx","year":"2023","unstructured":"von Arx, C. et al. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. Cancer Treat. Rev. 113, 102500 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"13810_CR20","doi-asserted-by":"publisher","first-page":"115534","DOI":"10.1016\/j.taap.2021.115534","volume":"421","author":"RL Best","year":"2021","unstructured":"Best, R. L. et al. Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy. Toxicol. Appl. Pharmacol. 421, 115534 (2021).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"13810_CR21","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s11864-023-01072-5","volume":"24","author":"T Grinda","year":"2023","unstructured":"Grinda, T., Rassy, E. & Pistilli, B. Antibody-drug conjugate revolution in breast cancer: The road ahead. Curr. Treat. Options Oncol. 24, 442\u2013465 (2023).","journal-title":"Curr. Treat. Options Oncol."},{"key":"13810_CR22","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1021\/acsmedchemlett.9b00310","volume":"10","author":"JA Costoplus","year":"2019","unstructured":"Costoplus, J. A. et al. Peptide-cleavable self-immolative maytansinoid antibody-drug conjugates designed to provide improved bystander killing. ACS Med. Chem. Lett. 10, 1393\u20131399 (2019).","journal-title":"ACS Med. Chem. Lett."},{"key":"13810_CR23","doi-asserted-by":"publisher","first-page":"2306309","DOI":"10.1002\/advs.202306309","volume":"11","author":"Y Guo","year":"2024","unstructured":"Guo, Y. et al. Rational identification of novel antibody-drug conjugate with high bystander killing effect against heterogeneous tumors. Adv. Sci. 11, 2306309 (2024).","journal-title":"Adv. Sci."},{"key":"13810_CR24","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s, J. et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N. Engl. J. Med. 386, 1143\u20131154 (2022).","journal-title":"N. Engl. J. Med."},{"key":"13810_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med."},{"key":"13810_CR26","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani, Y., Hagihara, K., Oitate, M., Naito, H. & Agatsuma, T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody\u2013drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 107, 1039\u20131046 (2016).","journal-title":"Cancer Sci."},{"key":"13810_CR27","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani, Y. et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA Topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin. Cancer Res. 22, 5097\u20135108 (2016).","journal-title":"Clin. Cancer Res."},{"key":"13810_CR28","doi-asserted-by":"publisher","first-page":"16729","DOI":"10.1021\/jp952956f","volume":"100","author":"SJ Marrink","year":"1996","unstructured":"Marrink, S. J. & Berendsen, H. J. C. Permeation process of small molecules across lipid membranes studied by molecular dynamics simulations. J. Phys. Chem. 100, 16729\u201316738 (1996).","journal-title":"J. Phys. Chem."},{"key":"13810_CR29","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1021\/jp980230o","volume":"102","author":"AK Ghose","year":"1998","unstructured":"Ghose, A. K., Viswanadhan, V. N. & Wendoloski, J. J. Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: An analysis of ALOGP and CLOGP methods. J. Phys. Chem. A 102, 3762\u20133772 (1998).","journal-title":"J. Phys. Chem. A"},{"key":"13810_CR30","doi-asserted-by":"publisher","first-page":"114408","DOI":"10.1016\/j.biopha.2023.114408","volume":"161","author":"A Samantasinghar","year":"2023","unstructured":"Samantasinghar, A. et al. A comprehensive review of key factors affecting the efficacy of antibody drug conjugate. Biomed. Pharmacother. 161, 114408 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"13810_CR31","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","volume":"11","author":"Z Su","year":"2021","unstructured":"Su, Z. et al. Antibody\u2013drug conjugates: Recent advances in linker chemistry. Acta Pharm. Sin. B 11, 3889\u20133907 (2021).","journal-title":"Acta Pharm. Sin. B"},{"key":"13810_CR32","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00216-006-0470-x","volume":"386","author":"A Yamaguchi","year":"2006","unstructured":"Yamaguchi, A. et al. Longitudinal diffusion behavior of hemicyanine dyes across phospholipid vesicle membranes as studied by second-harmonic generation and fluorescence spectroscopies. Anal. Bioanal. Chem. 386, 627\u2013632 (2006).","journal-title":"Anal. Bioanal. Chem."},{"key":"13810_CR33","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S0006-3495(01)76079-1","volume":"80","author":"Y Liu","year":"2001","unstructured":"Liu, Y., Yan, E. C. Y. & Eisenthal, K. B. Effects of bilayer surface charge density on molecular adsorption and transport across liposome bilayers. Biophys. J. 80, 1004\u20131012 (2001).","journal-title":"Biophys. J."},{"issue":"40","key":"13810_CR34","doi-asserted-by":"publisher","first-page":"29113","DOI":"10.1039\/D4RA04846F","volume":"14","author":"P Boonnoy","year":"2024","unstructured":"Boonnoy, P. et al. Cholesterol inhibits oxygen permeation through biological membranes: Mechanism against double-bond peroxidation. RSC Adv. 14(40), 29113\u201329121 (2024).","journal-title":"RSC Adv."},{"issue":"35","key":"13810_CR35","doi-asserted-by":"publisher","first-page":"8583","DOI":"10.1021\/acs.jpclett.1c02077","volume":"12","author":"E Canepa","year":"2021","unstructured":"Canepa, E. et al. Cholesterol hinders the passive uptake of amphiphilic nanoparticles into fluid lipid membranes. J. Phys. Chem. Lett. 12(35), 8583\u20138590 (2021).","journal-title":"J. Phys. Chem. Lett."},{"key":"13810_CR36","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher, A. H. & Brown, M. P. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required. Br. J. Cancer 117, 1736\u20131742 (2017).","journal-title":"Br. J. Cancer"},{"key":"13810_CR37","doi-asserted-by":"publisher","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","volume":"51","author":"S Kim","year":"2023","unstructured":"Kim, S. et al. PubChem 2023 update. Nucleic Acids Res. 51, D1373\u2013D1380 (2023).","journal-title":"Nucleic Acids Res."},{"key":"13810_CR38","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1021\/acs.molpharmaceut.9b00437","volume":"16","author":"IK Sokka","year":"2019","unstructured":"Sokka, I. K., Ekholm, F. S. & Johansson, M. P. Increasing the potential of the Auristatin cancer-drug family by shifting the conformational equilibrium. Mol. Pharm. 16, 3600\u20133608 (2019).","journal-title":"Mol. Pharm."},{"key":"13810_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-15674-1","volume":"7","author":"MP Johansson","year":"2017","unstructured":"Johansson, M. P., Maaheimo, H. & Ekholm, F. S. New insight on the structural features of the cytotoxic auristatins MMAE and MMAF revealed by combined NMR spectroscopy and quantum chemical modelling. Sci. Rep. 7, 1\u201310 (2017).","journal-title":"Sci. Rep."},{"key":"13810_CR40","doi-asserted-by":"publisher","first-page":"e202103520","DOI":"10.1002\/chem.202103520","volume":"28","author":"P Marzullo","year":"2022","unstructured":"Marzullo, P. et al. Maytansinol derivatives: Side reactions as a chance for new tubulin binders. Chem. Eur. J. 28, e202103520 (2022).","journal-title":"Chem. Eur. J."},{"key":"13810_CR41","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s10822-018-0150-x","volume":"32","author":"Q Zeng","year":"2018","unstructured":"Zeng, Q., Jones, M. R. & Brooks, B. R. Absolute and relative pKa predictions via a DFT approach applied to the SAMPL6 blind challenge. J. Comput. Aided Mol. Des. 32, 1179\u20131189 (2018).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"13810_CR42","unstructured":"Frisch, M. J. et al. Gaussian\u02dc16 Revision {C}.01. Preprint at (2016)."},{"key":"13810_CR43","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00214-007-0310-x","volume":"120","author":"Y Zhao","year":"2008","unstructured":"Zhao, Y. & Truhlar, D. G. The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: Two new functionals and systematic testing of four M06-class functionals and 12 other functionals. Theor. Chem. Acc. 120, 215\u2013241 (2008).","journal-title":"Theor. Chem. Acc."},{"key":"13810_CR44","doi-asserted-by":"publisher","first-page":"6378","DOI":"10.1021\/jp810292n","volume":"113","author":"AV Marenich","year":"2009","unstructured":"Marenich, A. V., Cramer, C. J. & Truhlar, D. G. Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions. J. Phys. Chem. B 113, 6378\u20136396 (2009).","journal-title":"J. Phys. Chem. B"},{"key":"13810_CR45","doi-asserted-by":"publisher","first-page":"7314","DOI":"10.1021\/ja010534f","volume":"123","author":"MD Liptak","year":"2001","unstructured":"Liptak, M. D. & Shields, G. C. Accurate pKa calculations for carboxylic acids using complete basis set and Gaussian-n models combined with CPCM continuum solvation methods. J Am. Chem. Soc. 123, 7314\u20137319 (2001).","journal-title":"J Am. Chem. Soc."},{"key":"13810_CR46","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/jcc.20090","volume":"25","author":"C Oostenbrink","year":"2004","unstructured":"Oostenbrink, C., Villa, A., Mark, A. E. & Van Gunsteren, W. F. A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS force-field parameter sets 53A5 and 53A6. J. Comput. Chem. 25, 1656\u20131676 (2004).","journal-title":"J. Comput. Chem."},{"key":"13810_CR47","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00249-011-0700-9","volume":"40","author":"N Schmid","year":"2011","unstructured":"Schmid, N. et al. Definition and testing of the GROMOS force-field versions 54A7 and 54B7. Eur. Biophys. J. 40, 843\u2013856 (2011).","journal-title":"Eur. Biophys. J."},{"key":"13810_CR48","doi-asserted-by":"publisher","first-page":"5834","DOI":"10.1021\/acs.jctc.8b00768","volume":"14","author":"M Stroet","year":"2018","unstructured":"Stroet, M. et al. Automated topology builder version 3.0: Prediction of solvation free enthalpies in water and hexane. J. Chem. Theory Comput. 14, 5834\u20135845 (2018).","journal-title":"J. Chem. Theory Comput."},{"key":"13810_CR49","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1021\/ct900487a","volume":"6","author":"D Poger","year":"2010","unstructured":"Poger, D. & Mark, A. E. On the validation of molecular dynamics simulations of saturated and cis-monounsaturated phosphatidylcholine lipid bilayers: A comparison with experiment. J. Chem. Theory Comput. 6, 325\u2013336 (2010).","journal-title":"J. Chem. Theory Comput."},{"key":"13810_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1\u20132","author":"MJ Abraham","year":"2015","unstructured":"Abraham, M. J. et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1\u20132, 19\u201325 (2015).","journal-title":"SoftwareX"},{"key":"13810_CR51","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/bip.360230807","volume":"23","author":"J Hermans","year":"1984","unstructured":"Hermans, J., Berendsen, H. J. C., Van Gunsteren, W. F. & Postma, J. P. M. A consistent empirical potential for water\u2013protein interactions. Biopolymers 23, 1513\u20131518 (1984).","journal-title":"Biopolymers"},{"key":"13810_CR52","doi-asserted-by":"publisher","first-page":"014101","DOI":"10.1063\/1.2408420","volume":"126","author":"G Bussi","year":"2007","unstructured":"Bussi, G., Donadio, D. & Parrinello, M. Canonical sampling through velocity rescaling. J Chem. Phys. 126, 014101 (2007).","journal-title":"J Chem. Phys."},{"key":"13810_CR53","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1063\/1.448118","volume":"81","author":"HJC Berendsen","year":"1984","unstructured":"Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., DiNola, A. & Haak, J. R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81, 3684\u20133690 (1984).","journal-title":"J. Chem. Phys."},{"key":"13810_CR54","doi-asserted-by":"publisher","first-page":"114107","DOI":"10.1063\/5.0020514","volume":"153","author":"M Bernetti","year":"2020","unstructured":"Bernetti, M. & Bussi, G. Pressure control using stochastic cell rescaling. J. Chem. Phys. 153, 114107 (2020).","journal-title":"J. Chem. Phys."},{"key":"13810_CR55","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1063\/1.464397","volume":"98","author":"T Darden","year":"1993","unstructured":"Darden, T., York, D. & Pedersen, L. Particle mesh Ewald: An N\u00b7log(N) method for Ewald sums in large systems. J. Chem. Phys. 98, 10089\u201310092 (1993).","journal-title":"J. Chem. Phys."},{"key":"13810_CR56","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1021\/ct100494z","volume":"6","author":"JS Hub","year":"2010","unstructured":"Hub, J. S., de Groot, B. L. & van der Spoel, D. g_wham\u2014A free weighted histogram analysis implementation including robust error and autocorrelation estimates. J. Chem. Theory Comput. 6, 3713\u20133720 (2010).","journal-title":"J. Chem. Theory Comput."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13810-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13810-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13810-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:17:25Z","timestamp":1757344645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13810-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13810"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13810-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5403308\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.C.\n                      Consulting\/Advisor\n                      :\u00a0Roche, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Lilly, Merck Sharp&Dohme, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics,\u00a0Scorpion Therapeutics,\u00a0Expres2ion Biotechnologies, Jazz Pharmaceuticals, Abbvie, BridgeBio, Biontech, Biocon, Circle Pharma.\n                      Honoraria\n                      : Roche, Novartis, Eisai, Pfizer, Lilly, Merck Sharp&Dohme, Daiichi Sankyo, Astrazeneca, Gilead, Steamline Therapeutics.\n                      Research funding to the Institution\n                      :\u00a0Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH\/Servier Affaires, Bayer healthcare, Eisai, F. Hoffman-La Roche, Guardanth Health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Iqvia, Queen Mary University of London.\n                      Stock\n                      : MAJ3 Capital, Leuko (relative).\n                      Travel, accommodation, expenses\n                      : Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo, Astrazeneca, Gilead, Merck Sharp&Dhome, Steamline Therapeutics.\n                      Patents\n                      :\u00a0(i) Pharmaceutical Combinations of A Pi3k Inhibitor and A Microtubule Destabilizing Agent. Javier Cort\u00e9s Cast\u00e1n, Alejandro Piris Gim\u00e9nez, Violeta Serra Elizalde. WO 2014\/199294 A. ISSUED, (ii) HER2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy. Aleix Prat, Antonio Llombart, Javier Cort\u00e9s. US 2019\/ 0338368 A1. LICENSED. J.P.-G.\n                      Advisory\u202fRole\n                      :\u00a0Lilly, Roche,\u202fEisai,\u202fDaichii\u202fSankyo,\u202fAstraZeneca, Seattle\u202fGenetics, Gilead, MSD.\n                      Travel\u202fexpenses\n                      :\u202fRoche.\u00a0M.G.\n                      Honoraria\n                      : Novartis, Gilead, AstraZeneca, Pfizer.\n                      Travel grants, accommodation\n                      : Roche, Pfizer, AstraZeneca, Gilead.\n                      Advisory role\n                      : Gilead, Novartis, AstraZeneca. C.S.\n                      Speaker bureau\n                      : AstraZeneca, Daiichi Sankyo.\n                      Travel\/accommodation\/expenses:\n                      Pfizer, Astrazeneca, Novartis, Lilly. L.G.-E.\n                      Consultant\/advisor\/speaker\n                      : AstraZeneca, Daiichi Sankyo, Gilead, Merck Sharp&Dhome, Lilly, Roche.\n                      Research funding to the institution\n                      : Roche. L.G.\n                      Speaker bureau\n                      : Novartis, Daiichi Sankyo. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28715"}}